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Results: 85 patients who met the selection criteria were analyzed. The 
demographic features were - males 61%; Caucasians - 54%; African 
Americans - 38%; history of pulmonary disorder- 41%; NSCLC- 78%; 
PS- 0,1- 92%; Stage III- 89%. The median dose of TR was 5940 cGy. 
Radiation ﬁelds have been retrospectively assessed in 41 patients to 
date. 9 of the 41 patients (22%) received involved ﬁeld radiation. 53 
patients (63%) received Cisplatin/Etoposide and 20 patients (24%) 
received Carboplatin/Paclitaxel. 75 patients (88%) received concurrent 
therapy. 31 patients (36%) developed RP; 15 (18%) had RTOG grade ≥ 
3 RP. Median time to development of RP was 4.6 months. Rate of RP 
in females and males was 42% vs. 33% (p=0.49). Rate of RP in patients 
with history of pulmonary disorder at baseline was 49% as compared to 
28% in others (p=0.068). 1 year hospitalization rate was 74% and 37% 
in RP and non-RP patients (p=0.0015). For all 85 patients, the median 
overall survival (OS) was 19.5 months (95% CI 16.4 - 23.3). Length of 
OS did not differ signiﬁcantly (p = 0.59) between the 31 patients who 
had RP vs. the 54 patients who had no RP (median OS: 19.3 vs. 18.8 
months, respectively). The median survival of the 15 patients who had 
severe RP was 16.6 months.
Conclusions: The rate of severe RP in these 85 lung cancer patients, 
treated off-protocol with CT and TR, is higher than that reported in 
clinical trials. Despite higher morbidity (i.e., increased hospitalization) 
in patients with RP, survival duration did not differ signiﬁcantly by RP 
status.
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Adjuvant docetaxel plus carboplatin versus observation in 
patients with completely resected stage IB-IIIA non-small-cell lung 
cancer: preliminary results of the Chinese Society of Lung Cancer 
randomised controlled trial (CSLC201)
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Background: Four larger clinical trials, IALT, NCIC-JBR10, ANITA 
and Japanese UFT trial, have shown signiﬁcant OS advantages with ad-
juvant chemotherapy. Unless vinorelbine plus cisplatin, whether other 
third generation doublet chemotherapy regimen improves survival of 
patients with non-small-cell lung cancer (NSCLC) is not known. We 
aimed to compare the effect of adjuvant docetaxel plus carboplatin 
versus observation on survival in patients with completely resected 
NSCLC.
Methods: 82 patients with stage IB-IIIA NSCLC from 3 centres in 
China were randomly assigned to 75mg/m(2) docetaxel plus AUC=5 
carboplatin (n=43) or to observation (n=39). The primary endpoint was 
disease free survival (DFS). The second endpoint was overall survival, 
response rate in the chemo group and safety. Analysis was by intention 
to treat. This trial was closed early by the EC as adjuvant chemotherapy 
became a standard therapy for resected NSCLC in 2005.
Results: 43 patients in the chemotherapy group and 39 in the observa-
tion group received their assigned treatment. 45 (54.9%) patients had 
stage IB disease, 20 (24.4%) had stage II disease, and 17 (20.7%) had 
stage IIIA disease. Adenocarcinoma accounted for 62.2% (51 cases, 
Tab.1). The median chemotherapy cycles were 3. After a median 
follow-up of 29.5 months (range 3-51), median disease free survival 
time is not reached in the chemotherapy group and 34 months in the 
observation group (p=0.0173). Median overall survival in both groups 
is not reached (Fig.1). 
Conclusion: Adjuvant docetaxel plus carboplatin extends disease free 
survival in patients with completely resected NSCLC.
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Can the patients with locally advanced non-small cell lung 
cancer (LANSCLC) tolerate 60mg/m2 docetaxel on day 1 and 
30mg/m2 Cisplatin on day 1 and 2 for 2 cycles during concurrent 
radiotherapy (CCRT) after 2-3 cycles of induction chemotherapy?
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School of Oncology, Beijing, China
Background: CCRT plus consolidation chemotherapy is a standard 
treatment of LANSCLC. But there is still a great controversy about 
the chemotherapy regimen for CCRT. A group of physician in Korean 
found 20mg/m2 docetaxel plus 20mg/m2 cisplatin, weekly is maximum 
tolerated dose for patients with LANSCLC during 6 weeks of 63Gy 
radiotherapy. The purpose of our trial was to determine whether the 
NSCLC patients after 2-3 cycles of induction chemotherapy can toler-
ate the chemotherapy regimen of 60 mg/m2 T and 60mg/m2, 2 cycles in 
6 weeks radiotherapy, based on toxicity. 
Methods: Previously untreated 9 patients with histological/cytologi-
cally proven Stage III non-small-cell lung cancer were eligible after 
induction chemotherapy for 2-3 cycles. Followed a month later by con-
tinual radiotherapy (62-70Gy in 31-35 fractions, 6-7weeks) delivered 
concurrently with cisplatin and docetaxel. The dosage of level 1 was 
of 56 mg/m2 docetaxel, on day 1 and 28mg/m2 cisplatin, on day 1 and 
day 2, 2 cycles during CCRT. The radiotherapy model was conformal 
radiotherapy or intensity modulated radiotherapy. The dosage of level 
2 was 60 mg/m2 docetaxel, on day 1 and 30 mg/m2 on day 1 and day 2. 
Response rate was evaluated as complete remission (CR), partial remis-
sion (PR), stable disease (SD) and progressive disease (PD). 
Results: Nine patients were enrolled, with median age of 58, (43-70). 
Seven patients were male, 2 female. The ECOG scores of 4 patients 
were 0, and ECOG scores of 5 patients were 1. The loss of weight of 
8 patients was 0%, that of one patient was ≤5% in three months before 
diagnosis. Seven patients were with squamous cell carcinoma, 2 with 
adenocarcinoma. The objective response was as follows: PR 8/9, SD 
1/9. The toxicities were showed in table 1.
Conclusions: The patients with LANSCLC can tolerate 60mg/m2 
docetaxel and 60mg/m2 cisplatin for 2 cycles during concurrent radio-
therapy after 2-3 cycles of induction chemotherapy.
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Analysis of clinical and dosimetric factors associated with severe 
radiation pneumonitis in locally advanced Non-Small-Cell-Lung-
Cancer patients treated with concurrent chemotherapy and 
intensity-modulated radiotherapy (IMRT)
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Purpose: To retrospectively evaluate clinical and dosimetric factors 
associated with severe (grade≥3) radiation pneumonitis in patients 
after concurrent chemotherapy and intensity-modulated radiotherapy 
(IMRT).
Methods: We retrospectively analyzed 94 locally advanced NSCLC 
patients treated with concurrent chemotherapy and IMRT between 
May 2005 and September 2006. Radiation pneumonitis was graded 
according to Common Terminology Criteria for Adverse Events version 
3.0. The following clinical parameters were considered: gender, age, 
smoking and diabetes history, history of chronic obstructive pulmonary 
disease (COPD), induction chemotherapy, concurrent chemotherapy 
regimens, performance status and forced expiratory volume in 1 second 
(FEV1). Dosimetric factors including mean lung dose (Dmean), rV5-
V60 relative volumes of lung receiving more than a threshold dose D 
of radiation (rVD), where values of D considered were 5˚C 60 Gy in 
increments of 5 Gy), prescribed dose (63GY/35f/7w vs 60Gy/30f/6w), 
and normal tissue complication probability (NTCP) values were 
analysed. DVHs data and NTCP values were collected for both lungs 
considered as a parallel organ. Pearson Chi-Square test was performed 
to compare clinical parameters between patients who developed severe 
RP and those who did not. Univariate and multivariate logistic regres-
sion analyses were performed to evaluate data for association between 
clinical and dosimetric factors and severe RP. The study was approved 
by the institutional reviewboard. 
Results: Of 94 patients, 11 (11.7%) develop severe (grade≥3) radiation 
pneumonitis; 6 (6.4%), grade 3; 2(2.1%), grade 4; and 3 (3.2%)grade 
5. Univariate analyses show that Sex, age (≤60vs>60), smoking and 
diabetes history, induction chemotherapy, concurrent chemotherapy 
regimens, PS(≤70vs>70) and prescribed dose did not signiﬁcantly dif-
fer between patients who developed severe RP and those who did not. 
However, NTCP, MLD, rV5-V60, COPD and FEV1 were associated 
with severe RP (p<0.05). In multivariate analysis, NTCP (p=0.001) and 
rV10(p=0.015) was the most signiﬁcant factors associated with severe 
(grade≥3) radiation pneumonitis. The incidences of Grade≥3 pneumo-
nitis in the group with NTCP>4.2% and NTCP <4.2% were 43.5% and 
1.4%, respectively (p<0.01). The incidences of Grade≥3 pneumonitis in 
the group with rV10 <51.2% and rV10 >51.2% were 5.6% and 30.4%, 
respectively (p<0.01).
Conclusions: NTCP and rV10 is useful indicator of risk for develop-
ment of severe (grade≥3) radiation pneumonitis in NSCLC patients 
after concurrent chemotherapy and intensity -modulated radiotherapy 
(IMRT).
NSCLC: Cytotoxic Chemotherapy
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A multicenter phase II randomized study of paclitaxel (P) and 
carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as 
second-line treatment in patients with non-small cell lung cancer 
(NSCLC) pretreated with non-platinum based chemotherapy
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Background: Limited data is available on the activity of platinum-
containing doublets as second-line treatment of NSCLC patients who 
received non-patinum based ﬁrst-line therapy. We performed a multi-
center randomized phase II trial to compare PC and oVC in NSCLC 
patients (pts) pretreated with ﬁrst-line docetaxel (D)/gemcitabine (G).
Methods: Pts with stage IIIB/IV NSCLC and adequate performance 
status (PS), haematological, hepatic, cardiac and renal function pre-
treated with DG were eligible. Pts received P 140 mg/m2 combined 
with C AUC3 or oV 45 mg/m2 combined with C AUC3 on days 1 and 
15 of a 30-day cycle. Stratiﬁcation was done for PS and response to 
prior treatment. Primary endpoint was response rate (RR) and second-
ary endpoints were time to progression (TTP), survival and toxicity. 
Results: 140 pts were randomized to PC (n= 65) or oVG (n= 75). 
Median age was 60 yrs for both arms (range, 39-74 and 38-79, respec-
tively) and PS was 0-1 in 91% and 85%, for PC and oVC, respectively. 
In an intension-to-treat analysis, signiﬁcantly more responders were ob-
served in the PC arm with an overall RR of 19.4% vs 4.2% (p=0.006). 
After a median follow up time of 5.4 (range 0.5-30) months, median 
TTP was 3.2 (range, 0.5-23.7) vs 2.8 (range, 0.5-18.5) for PC and 
oVC, respectively (p=0.150). Median overall survival was 6.3 (range, 
0.5–26.2) vs 6.1 (range, 0.5–30) months and 1-yr survival was 29.4% 
vs 27.5% for PC and oVC, respectively (p=0.586). The two arms ex-
hibited similar rates of grade 3 and 4 toxicity. 
Conclusions: A higher response rate that was not translated to a sur-
vival beneﬁt was recorded for the PC arm. No signiﬁcant differences in 
toxicity rates were observed. 
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A phase II trial of weekly cisplatin and docetaxel in advanced non-
small cell lung cancer (NSCLC)
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Background: Every 3-week cisplatin doublets used to treat advanced 
NSCLC carry a signiﬁcant risk of renal and other toxicities and can 
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